Microtubule-stabilizing agents (MTSAs), including the taxanes and epothilones, are effective chemotherapeutic agents for the treatment of many cancers. Neuropathy is a major adverse effect of MTSA-based chemotherapy, with severe peripheral neuropathy (grade 3 or 4) occurring in as many as 30% of patients treated with a MTSA. MTSA-induced neuropathy usually resolves gradually after cessation of the treatment. The most reliable method to accurately assess MTSA-induced neuropathy is by clinical evaluation, although additional techniques are being developed and evaluated. Among MTSA-induced neuropathy, the most extensively studied is that induced by taxanes; such a neuropathy usually presents as sensory neuropathy and is more common with paclitaxel than docetaxel. The incidence of MTSA-induced neuropathy seems to depend on the MTSA dose per treatment cycle, the schedule of treatment, and the duration of the infusion. Although there have been several small clinical trials with neuroprotective agents, early recognition and supportive care are the best approaches for prevention and management of MTSA-induced neuropathy. In the future, research should focus on elucidating the mechanism of MTSA-induced neuropathy, developing reliable in vivo and in vitro preclinical models to study MTSA-induced neuropathy, developing a more reliable grading system for MTSA-induced neuropathy, developing more reliable methods for evaluating MTSA-induced neuropathy, and evaluating the efficacy of potential neuroprotective agents in clinical trials.
INTRODUCTION
Microtubule-stabilizing agents (MTSAs), including the taxanes and epothilones, stabilize microtubules, block mitosis, and induce cell death.
1,2 Taxanes include polyoxyethylated castor oil-based paclitaxel, docetaxel, and ABI-007 and are effective chemotherapeutic agents for various cancers. ABI-007 is a new polyoxyethylated castor oil-free formulation of paclitaxel with good antitumor activity in phase III clinical trials of breast cancer. [3] [4] [5] [6] Epothilones are newly emerged MTSAs in active clinical trials and include ixabepilone (BMS-247550), BMS-310705, patupilone (EPO906), epothilone D (KOS-862), and ZK-EPO. 7 A major toxicity associated with MTSAbased chemotherapy is peripheral neuropathy (PN). 8, 9 Severe PN (National Cancer Institute [NCI] Common Toxicity Criteria grade 3 or 4) occurs more frequently in paclitaxel-based chemotherapy than in docetaxel-based chemotherapy (Tables 1 and 2) . A clinical assessment, including a physical examination, is currently the most reliable method to assess MTSA-induced PN because we lack more reliable objective methods. Although neuroprotective agents such as amifostine have been evaluated in clinical trials, no neuroprotective agent has performed better than early recognition and supportive care. [32] [33] [34] [35] [36] In this review, we summarize the characteristics, assessment, and management of MTSA-induced PN, mainly based on breast cancer trials. We also point out areas of future research.
PRECLINICAL INVESTIGATIONS ON THE MECHANISM OF MTSA-INDUCED NEUROPATHY
PN is caused by morphologic or functional abnormalities in peripheral nerves and is separated into axonopathy (axonal abnormalities) or myelinopathy (myelin sheath abnormalities). 37 MTSA-induced PN presents as axonopathy or axonopathy plus myelinopathy. The mechanism of MTSA-induced PN is unclear. However, because the survival and function of neurons require that proteins and other components be actively transported along long axons from a neuron's cell body to its distal synapses, MTSA treatment likely interrupts this active transport.
Addition of paclitaxel (10 g/mL) to dorsal root ganglia cell cultures inhibited anterograde axonal transport, 38 which was reversible and did not damage cells. Also, incubation of rat sciatic nerve with paclitaxel 200 mol/L induced vesicle accumulation on both proximal and distal sides of the nerve, indicating that paclitaxel treatment blocked fast axonal transport. 39 In another study involving rats, injection of paclitaxel into neurons induced microtubule aggregation without degenerative changes in peripheral nerves 40 ; microtubules aggregated first in Schwann cells and then in axons. Finally, systemic paclitaxel injection of rats induced microtubules accumulation in Schwann cells and axons but caused minimal damage to their sciatic nerve. 41 Microtubule aggregation was not observed in sural nerve biopsies from patients with MTSA-induced neuropathy. 42, 43 Thus, the mechanism of MTSA-induced neuropathy remains unclear.
INCIDENCE AND RISK FACTORS OF MTSA-INDUCED NEUROPATHY
The incidence of MTSA-induced PN depends on risk factors including dose per cycle, treatment schedule, duration of infusion, cumulative dose, and comorbidity such as diabetes. Associations between these risk factors and the incidence of MTSA-induced PN have been confirmed in clinical trials, as discussed below. [10] [11] [12] 44 Although the clinical response of tumors to a specific MTSA is the most important reason to select a chemotherapy regimen, it is also prudent to evaluate the risk of developing PN associated with each chemotherapy regimen, especially for patients already at high risk of neuropathy.
Dose per Cycle
The incidence of PN depends on the dose of MTSA per treatment cycle. In a randomized study of paclitaxel in breast cancer, severe PN (WHO grade 3 or 4) was observed in 7% of patients receiving paclitaxel at 175 mg/m 2 but in only 3% of patients receiving paclitaxel at 135 mg/m 2 . 44 In the Cancer and Leukemia Group B (CALGB) 9342 trial, grade 3 or 4 sensory PN was observed in 33% of patients receiving paclitaxel at 250 mg/m 2 (n ϭ 149), in 19% of patients receiving paclitaxel at 210 mg/m 2 (n ϭ 152), and in 7% of patients receiving paclitaxel at 175 mg/m 2 (n ϭ 150; P ϭ .0001).
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In a phase II trial of breast cancer, grade 3 or 4 sensory PN was observed in 4% of patients receiving ABI-007 at 100 mg/m 2 weekly (n ϭ 106) and in 17% of patients receiving ABI-007 at 125 mg/m 2 weekly (n ϭ 75).
4

Treatment Schedule
There is a significant difference in the incidence of PN depending on treatment schedules. In the phase III CALGB 9840 trial of breast cancer comparing paclitaxel 80 mg/m 2 weekly (n ϭ 234) with paclitaxel 175 mg/m 2 every 3 weeks (n ϭ 230), grade 3 or 4 sensory PN occurred in 19% of patients in the weekly infusion group and in 12% of patients in the every 3 weeks group (P ϭ .001).
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Duration of Infusion
Polyoxyethylated castor oil-based paclitaxel can be infused over 1 hour, 3 hours, or 24 hours. Mielke et al 45 reported the pharmacodynamic effect of paclitaxel on the development of PN. There was no difference in the development of PN between the 1-hour and 3-hour infusion of polyoxyethylated castor oil-based paclitaxel 100 mg/m 2 . There was no significant difference in the peak concentration of total paclitaxel, unbound paclitaxel, and polyoxyethylated castor oil between patients with and without PN. However, the duration of the time of total paclitaxel above the concentration of 0.05 mol/L (Ն 10.6 hours) was the most important pharmacokinetic risk factor for the development of PN (relative risk ϭ 18.43; P ϭ .036).
In the National Surgical Adjuvant Breast and Bowel Project B-26 trial of breast cancer, grade 3 or 4 PN was observed in 22% of patients receiving a 3-hour infusion of paclitaxel (250 mg/m 2 /cycle; n ϭ 279) and in 13% of patients receiving a 24-hour infusion (n ϭ 284). 12 In a randomized phase III trial of paclitaxel (135 or 175 mg/m 2 ) in patients with ovarian cancer, there was no significant difference in the incidence of grade 3 or 4 PN between the 3-hour (n ϭ 187) and 24-hour (n ϭ 204) infusion (0.7% v 0.6%, respectively).
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Cumulative Dose
The onset of PN generally depends on the cumulative dose of MTSAs. In a randomized phase III study comparing docetaxel 100 mg/m 2 every 3 weeks (n ϭ 225) with paclitaxel 175 mg/m 2 every 3 weeks (n ϭ 224) in metastatic breast cancer, the mean cumulative dose to onset of grade Ն 2 PN was 371 mg/m 2 for docetaxel and 715 mg/m 2 for paclitaxel. 47 In patients treated with ixabepilone (every 3 weeks or daily ϫ 5 every 3 weeks), the median onset of grade Ն 2 PN occurred after five to six cycles.
22,48
Other Risk Factors
Other risk factors may include diabetes mellitus, concurrent administration of cisplatin, or age with limited data. PN is a major complication of diabetes mellitus, and grade 3 or 4 sensory neuropathy has been reported in diabetic patients with cancer who were treated with high-dose paclitaxel. 49, 50 In a retrospective analysis of paclitaxel-induced PN in 18 diabetic patients, neuropathic symptoms were exacerbated in 50% of patients; these symptoms then worsened in 11% of these patients to grade 3 neuropathy.
51
Because platinum compounds induce PN, the possibility that coadministration of platinum compounds increased the incidence of MTSA-induced PN was examined in a phase III trial, in which 327 patients were randomly assigned either to paclitaxel (175 mg/m 2 ) and carboplatin every 3 weeks or to paclitaxel (175 mg/m 2 ) and epirubicin every 3 weeks. Results showed that grade 3 or 4 PN occurred in 2.5% of patients in both groups. 52 However, a smaller prospective analysis of neurotoxicity of combined paclitaxel and cisplatin treatment in 21 patients with solid tumors found that patients with pre-existing neuropathy experienced more grade 3 or 4 PN earlier in the treatment and at a lower cumulative paclitaxel dose (Ͻ600 mg/m 2 ) than patients without pre-existing neuropathy.
53
Older patients are more prone to MTSA-induced PN. In a phase II trial of paclitaxel (150 mg/m 2 weekly), age was significantly associated with neurotoxicity during cycle 2 (P ϭ .008). 54 There has been interest in various genetic predispositions for neuropathy, such as Wlds (slow Wallerian degeneration gene) or CYP3A genotypes.
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ASSESSMENT OF MTSA-INDUCED NEUROPATHY
Clinical Assessment
Symptoms. Accurate information must be ascertained on the onset, distribution, and severity of neuropathic symptoms and on their interference of daily activities. Sensory neuropathy presents as paresthesia, numbness, and pain in the feet and hands, 60 with symptoms generally appearing in the toes and then in the fingers. 61 Paresthesia occurs in distal lower extremities with a glove-and-stocking distribution and is most severe on plantar surfaces. 62 The severity of most symptoms is mild to moderate, and symptoms generally disappear on cessation of therapy. 44, 60, 63 Acute tingling in fingertips and toes may occur within 24 hours after paclitaxel infusion. 62 Paroxystic pain reaction seems mainly to involve muscles and bones of lower extremities and usually occurs 2 to 4 days after paclitaxel infusion.
64,65
Motor neuropathy is usually mild and presents as muscle weakness such as foot drop or difficulty in climbing stairs. 50, 66 Fine motor skills (eg, buttoning a shirt or putting on earrings) may be diminished.
62
Physical examination. The first sign of sensory neuropathy is an elevated vibratory perception threshold in distal extremities 60 and is often associated with loss of pain and temperature sensation. 67 The vibratory perception threshold increases more in feet than in hands. 68 The sense of position is usually lost in grade 3 or 4 neuropathy. MTSA-induced neuropathy is frequently manifested by decreased deep-tendon and ankle reflexes. 69 Motor neuropathy presents as muscle wasting, weakness, and fasciculation.
Neuropathy grading. Neuropathy is graded by subjective complaints of patients and physical examinations by clinicians. The most widely used grading systems are the NCI Common Toxicity Criteria, 70,71 Eastern Cooperative Oncology Group criteria, 72 and WHO criteria 73 (Table 3 ). The use of subjective patient complaints to assess neuropathy introduces large variations between assessments, and because clinical examinations depend on patient cooperation, this method is not entirely objective.
74,75 Although these grading systems have been widely used, limitations result from intra-and interobserver variation and from the inconsistent interpretation of components of these grading systems (Table 4) .
76,77
Questionnaire
Certain chemotherapy-induced toxicities (eg, pain or discomfort) cannot be measured objectively but have a high impact on quality of life (QOL) and treatment decisions. Questionnaires assess symptoms via patient-based measurements of chemotherapy-induced toxicities, and their analyses can help to determine the impact of such toxicities on QOL. 78 The Functional Assessment of Cancer TherapyTaxane system and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 are self-reporting instruments that measure health-related QOL in patients receiving chemotherapy.
78,79 These questionnaires query physical, social, emotional, and functional well-being including neurologic symptoms. These systems have been validated in randomized trials.
80-84 Thus, a questionnaire-based assessment of symptoms may be useful for measuring subjective MTSA-induced symptoms.
Quantitative Sensory Testing
Quantitative sensory testing (QST) is used to overcome interobserver discordance when assessing neurologic dysfunction. It measures the sensory threshold for a particular stimulus, such as vibration, by delivering a stimulus many times at various intensities via a specific algorithm. 85 A prospective analysis of paclitaxel-induced neuropathy investigated the utility of QST to assess chemotherapy-induced neuropathy. 86 The most sensitive test of QST was the vibration threshold of great toes, but QST was less sensitive for diagnosis of PN than clinical assessment.
76,86 Although QST is relatively simple, noninvasive, and easily repeated, it may not have significant advantage to assess MTSA-induced neuropathy. 48 Because these tests have not been evaluated in chemotherapy-induced PN, they need to be validated in a large prospective trial.
Electrophysiologic Testing
Nerve conduction study (NCS) and needle electromyography (EMG) are also used to objectively assess PN. Axonal neuropathy is identified by NCS as a low compound muscle action potential and by needle EMG as fibrillation; pure demyelinating neuropathy is identified by NCS as slow conduction velocity and prolonged distal latencies and by needle EMG as no fibrillation or positive sharp wave activity.
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In paclitaxel-induced neuropathy, both axonal degeneration and demyelination patterns are possible on NCS, 96 and frequently, sensory nerve potentials of the sural nerve are reduced or absent.
42,96
Docetaxel-induced PN showed low amplitude motor and sensory potentials on NCS.
61 Thus, although both tests seem to provide objective evidence of MTSA-induced neuropathy, additional studies are required to determine their sensitivity and specificity.
Histologic Examination
Although histologic confirmation of MTSA-induced neuropathy is desirable, a nerve biopsy may permanently damage the nerve fiber sampled. Histologic examination of sural nerve or peroneal nerve from patients with taxane-induced neuropathy have identified axonal degeneration, reduced myelinated fiber density, and the loss of large fibers.
42,61,97 Paclitaxel and docetaxel induced similar histologic changes. Although nerve biopsy is helpful for diagnosis of MTSAinduced neuropathy, the utility of this invasive procedure needs to be further validated.
MANAGEMENT
No specific treatments for MTSA-induced PN are available. MTSAinduced PN generally improves when MTSA dose is reduced or MTSA therapy is delayed or completed. 61, 98, 99 Approximately half of the patients with PN by polyoxyethylated castor oil-based paclitaxel experienced the improvement of PN within 9 months after cessation of paclitaxel treatment. 68 Grade 3 or 4 PN induced by ABI-007 improved in a median 22 days after interruption of treatment. 6 The median interval to improvement of grade Ն 2 PN induced by ixabepilone was 46 days for the every-3-week schedule 22 and 15 days for the daily ϫ 5 every-3-week schedule.
48
Management of MTSA-Induced Neuropathic Pain
Relief of paclitaxel-induced neuropathic pain by 10 to 50 mg of amitriptyline has been reported. 99 In addition, amelioration of taxane-induced myalgia/arthralgia by gabapentin (300 mg tid for 2 days before and for 5 days after taxane infusion) was retrospectively reported in six of 10 patients. 100 Gabapentin 400 mg tid was also used to relieve paclitaxel-induced severe myalgia. 101 Thus, amitriptyline and gabapentin may be helpful for the management of MTSAinduced neuropathic pain.
Neuroprotective Agents
Several types of neuroprotective agents have been tested for MTSA-induced neuropathy in animal models and clinical trials. Agents evaluated for potential neuroprotective effect in taxane-based chemotherapy are listed in Table 5 . Disodium 2,20-dithio-bisethanesulfonate (BNP7787). BNP7787 is reduced to mesna (sodium 2-mercaptoethanesulfonate) in the kidney and liver. [124] [125] [126] Although the mechanism of neuroprotective effect of BNP7787 in MTSA-induced neuropathy is unclear, a phase I trial found that BNP7787 substantially reduced the overall incidence of grade Ն 2 paclitaxel-induced neuropathy.
111 BNP7787 is currently being evaluated as a neuroprotective agent for paclitaxel-induced neuropathy in a phase III trial of patients with metastatic breast cancer.
112
Glutamine. Glutamine has ameliorated paclitaxel-induced neuropathy in an animal model. 127 In a double-blind, randomized, crossover trial of 36 patients receiving glutamine 10 g tid orally for 5 days with paclitaxel (Յ 175 mg/m 2 ), glutamine intake did not affect the development or severity of paclitaxel-induced myalgias and arthralgias. 33 When tested in a high-dose paclitaxel protocol (825 mg/m 2 ), 34 in which 33 control patients did not receive glutamine but 12 patients received glutamine 10 g tid orally for 4 days after completion of paclitaxel infusion, patients treated with oral glutamine, compared with patients not treated with glutamine, developed less moderate to severe dysesthesias (8% v 40%, respectively; P ϭ .047) and numbness in the fingers (33% v 73%, respectively; P ϭ .016), comparing pre-and postpaclitaxel treatment measurements. However, this finding needs to be validated in randomized placebo-controlled clinical trials. Vitamin E. Treatment with vitamin E may reduce neurotoxicity, especially cisplatin-induced neurotoxicity.
128,129 A randomized controlled trial for prophylaxis against chemotherapy-induced neuropathy 118 randomly assigned 16 patients to vitamin E 300 mg (Х 450 U) bid during chemotherapy (cisplatin, paclitaxel, or combination of cisplatin and paclitaxel) and up to 3 months after its completion and assigned 15 patients to no supplementation. Vitamin E supplementation was associated with significantly lower incidence of neuropathy (all grades) compared with no supplementation (25% v 73.3%, respectively; P ϭ .019). Although there is a report regarding the harmful effects of high-dose vitamin E (Ն 400 U/d), data regarding both risks and benefits of vitamin E supplementation for MTSA-induced PN are still preliminary. 130 The efficacy of neuroprotective agents needs to be validated in well-designed, randomized, placebo-controlled trials. Currently, lamotrigine (NCCTG-N01C3), amifostine (NCT00078845), dimesna (CALGB-30303), and BNP7787 (DMS30203R) are being evaluated in phase II or III clinical trials of MTSA-containing chemotherapy regimens for the prevention of chemotherapyinduced neuropathy.
110,113,119,131
Current Approach to the Management of MTSAInduced Neuropathy
Early detection of PN during MTSA-based chemotherapy is critical to prevent progression to grade 3 or 4 PN. If grade Ն 2 PN is diagnosed, it is prudent to hold MTSA until PN improves to at least grade 1, and then resume MTSA at a reduced dose. At present, there is no test that can be recommended to predict PN, but future clinical trials with tests discussed in this review are critical to advance the field. Gabapentin has been shown to provide relief of symptoms such as tingling or neuropathic pain and can be recommended.
FUTURE DIRECTIONS
Because understanding the exact mechanism of MTSA-induced neuropathy is essential for its management and prevention, reliable in vitro and animal models of MTSA-induced neuropathy should be developed. Current neuropathy grading systems should be consolidated into a reliable system so that neurotoxicity data from different clinical trials can be objectively compared. The reporting systems of clinical trials need to be standardized to collect more accurate data regarding MTSA-induced PN such as onset and duration of PN and cumulative dose. New measures for noninvasive evaluation of MTSAinduced neuropathy are needed to decrease interobserver and intraobserver variation in assessing MTSA-induced neuropathy. Finally, effective neuroprotective agents should be developed to prevent MTSA-induced neuropathy. 
